Top ▲

CS1 (CD319)

Click here for help

Immunopharmacology Ligand target has curated data in GtoImmuPdb

Target id: 2850

Nomenclature: CS1 (CD319)

Family: CD molecules

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 335 1q23.3 SLAMF7 SLAM family member 7
Mouse 1 333 1 H3 Slamf7 SLAM family member 7
Rat 1 342 13q24 Slamf7 SLAM family member 7
Previous and Unofficial Names Click here for help
CRACC | CS1-L | CD2-like receptor-activating cytotoxic cells
Database Links Click here for help
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
RefSeq Nucleotide
RefSeq Protein

Download all structure-activity data for this target as a CSV file go icon to follow link

Key to terms and symbols Click column headers to sort
Antibody Sp. Action Value Parameter Reference
elotuzumab Peptide Approved drug Primary target of this compound Immunopharmacology Ligand Hs Binding 8.1 pKd 2
pKd 8.1 (Kd 8.86x10-9 M) [2]
Immunopharmacology Comments
CS1 is a member of the signalling lymphocyte activation molecule (SLAM) receptor family. CS1 is a membrane glycoprotein primarily expressed on plasma cells. Homophilic interaction (i.e. interaction with itself) of CS1 induces B cell proliferation and autocrine cytokine secretion, thus playing a role in various immune functions.

CS1 is a validated molecular target for the development of novel immunotherapeutics with the potential to treat MM, a malignant disease of plasma cells which remains incurable despite advances in treatment (such as bortezomib, lenalidomide and immunotherapies in clinical trial). Indeed, a combination therapy containing the anti-CS1 mAb elotuzumab (elotuzumab + lenalidomide + dexamethasone), was FDA approved for MM in 2015. CS1 expression is also elevated in patients with systemic lupus erythematosus (SLE) [1], suggesting that this condition may also benefit from clinical CS1-targeted inhibition.
Cell Type Associations
Immuno Cell Type:  Macrophages & monocytes
Cell Ontology Term:   macrophage (CL:0000235)
monocyte (CL:0000576)
Immuno Cell Type:  Natural killer cells
Cell Ontology Term:   natural killer cell (CL:0000623)
Immuno Cell Type:  Dendritic cells
Cell Ontology Term:   dendritic cell (CL:0000451)
Immuno Cell Type:  B cells
Cell Ontology Term:   plasma cell (CL:0000786)
Immuno Cell Type:  T cells
Immuno Process Associations
Immuno Process:  Inflammation
Immuno Process:  Immune regulation
Immuno Process:  Cellular signalling
Immuno Process:  T cell (activation)
Immuno Process:  B cell (activation)
General Comments
This protein contains an immunoglobulin (Ig)-like domain that resembles the antibody variable domain, that has been coined the 'V-set domain'. The genes for all human V-set domain containing proteins are listed in HGNC gene group 590.


Show »

1. Kim JR, Mathew SO, Patel RK, Pertusi RM, Mathew PA. (2010) Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus. Clin Exp Immunol, 160 (3): 348-58. [PMID:20345977]

2. Williams M, Tso JY, Landolfi NF, Powers DB, Liu G. (2010) Therapeutic use of anti-CS1 antibodies. Patent number: US7709610. Assignee: Facet Biotech Corporation. Priority date: 28/05/2003. Publication date: 04/05/2010.

How to cite this page

CD molecules: CS1 (CD319). Last modified on 07/08/2019. Accessed on 20/06/2024. IUPHAR/BPS Guide to PHARMACOLOGY,